Antigen News and Research

RSS

TapImmune announces results from HER2/neu interim study on breast cancer

TapImmune Inc. has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events.

11 Jan 2013

Adolescents may lose hepatitis B virus protection despite vaccination as infants

New research reveals that a significant number of adolescents lose their protection from hepatitis B virus (HBV) infection, despite having received a complete vaccination series as infants. Results in the January 2013 issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, suggest teens with high-risk mothers (those positive for HBeAg) and teens whose immune system fails to remember a previous viral exposure (immunological memory) are behind HBV reinfection.

8 Jan 2013

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies.

7 Jan 2013

Researchers identify four new genetic regions associated with Behcet's disease

Researchers have identified four new regions on the human genome associated with Behcet's disease, a painful and potentially dangerous condition found predominantly in people with ancestors along the Silk Road.

7 Jan 2013

Manipulating T cells with iPSC techniques could help develop effective immune therapies

The human body contains immune cells programmed to fight cancer and viral infections, but they often have short lifespans and are not numerous enough to overcome attacks by particularly aggressive malignancies or invasions.

4 Jan 2013

Researchers create killer T lymphocytes from iPS cells

Researchers from the RIKEN Research Centre for Allergy and Immunology in Japan report today that they have succeeded for the first time in creating cancer-specific, immune system cells called killer T lymphocytes, from induced pluripotent stem cells (iPS cells).

4 Jan 2013

PSCA gene’s rs2294008 variant on T nucleotide may increase risk of bladder cancer

Patients who have inherited a specific common genetic variant develop bladder cancer tumors that strongly express a protein known as prostate stem cell antigen (PSCA), which is also expressed in many pancreatic and prostate tumors, according to research at the National Institutes of Health.

4 Jan 2013

Partin Tables to predict prostate cancer spread now updated

Prostate cancer experts at Johns Hopkins have developed an updated version of the Partin Tables, a tool to help men diagnosed with prostate cancer and their doctors to better assess their chance of a surgical cure. The updated tool, based on a study of more than 5,600 men treated at The Johns Hopkins Hospital from 2006 to 2011, is published in the Jan. 3 issue of the British Journal of Urology International.

3 Jan 2013

Active surveillance of prostate cancer patients encouraged

Active surveillance is an effective way of monitoring patients with low-risk prostate cancer and is associated with a low risk for systemic progression, say researchers.

31 Dec 2012

Immune response more complicated than thought

Researchers have found that the orientation and concentration of antibodies could determine the control of bacterial infection.

28 Dec 2012

BRCA testing impact on ovarian cancer prevention revealed

Research shows that women without a confirmed BRCA mutation are choosing to undergo screening or surgery to prevent ovarian cancer, despite little evidence to support their use in this population.

24 Dec 2012

MRI fused with ultrasound to strengthen prostate cancer diagnosis

Researchers have developed a technique that fuses magnetic resonance imaging with ultrasound to improve the detection and treatment of prostate cancer.

24 Dec 2012

Study examines role of race and ethnicity in stem cell donation

New research examining the role of race and ethnicity in an individual's decision to become a donor for hematopoietic cell transplantation (HCT) identifies several factors associated with varied participation rates in national donor registries across racial/ethnic groups. Results of this first-of-its-kind study are published online today in Blood, the Journal of the American Society of Hematology (ASH).

21 Dec 2012

Researchers develop game-changing diagnostic and prognostic genetic tests for prostate cancer

Researchers at the Kimmel Cancer Center at Jefferson (KCC) have developed potentially game-changing diagnostic and prognostic genetic tests shown to better predict prostate cancer survival outcomes and distinguish clinically-relevant cancers.

21 Dec 2012

US FDA approves raxibacumab for treating inhalational anthrax

The US Food and Drug Administration have approved the monoclonal antibody raxibacumab for treatment of inhalational anthrax, caused by breathing in spores of Bacillus anthracis.

19 Dec 2012

EMD Serono's L-BLP25 Phase III NSCLC trial does not meet primary endpoint

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III STARTa trial of its investigational product L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).

19 Dec 2012

Abiraterone improves outcomes for prostate cancer prior to chemo

Treatment with abiraterone acetate, an androgen biosynthesis inhibitor, may benefit patients with progressive metastatic castration-resistant prostate cancer who have not yet undergone chemotherapy, report researchers.

17 Dec 2012

New technique could help develop more-specific, cell-based immune therapies for cancer

A team led by Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, has shown for the first time the effectiveness of a new technique that could allow the development of more-specific, cell-based immune therapies for cancer.

17 Dec 2012

New diagnostic innovations could refine the way doctors detect prostate cancer

Despite the volume of prostate cancer tests and treatments, experts and their patients are continually challenged to predict the disease's course and apply the most appropriate treatment. Now, two new diagnostic innovations – the PCA3 urine test and a more targeted prostate biopsy technique - could refine the way doctors diagnose prostate cancer and, subsequently, the way patients elect to treat it.

15 Dec 2012

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

15 Dec 2012

Antigen News and Research

TapImmune announces results from HER2/neu interim study on breast cancer

Adolescents may lose hepatitis B virus protection despite vaccination as infants

Inovio, MVI collaborate to advance malaria vaccine development and new delivery technologies

Researchers identify four new genetic regions associated with Behcet's disease

Manipulating T cells with iPSC techniques could help develop effective immune therapies

Researchers create killer T lymphocytes from iPS cells

PSCA gene’s rs2294008 variant on T nucleotide may increase risk of bladder cancer

Partin Tables to predict prostate cancer spread now updated

Active surveillance of prostate cancer patients encouraged

Immune response more complicated than thought

BRCA testing impact on ovarian cancer prevention revealed

MRI fused with ultrasound to strengthen prostate cancer diagnosis

Study examines role of race and ethnicity in stem cell donation

Researchers develop game-changing diagnostic and prognostic genetic tests for prostate cancer

US FDA approves raxibacumab for treating inhalational anthrax

EMD Serono's L-BLP25 Phase III NSCLC trial does not meet primary endpoint

Abiraterone improves outcomes for prostate cancer prior to chemo

New technique could help develop more-specific, cell-based immune therapies for cancer

New diagnostic innovations could refine the way doctors detect prostate cancer

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News